-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-518528-54-00
1
2025-12-02
Active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), o
-
2025-521706-17-00
4
2025-11-25
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
-
2024-516602-28-00
7
2025-11-21
Advanced Solid Tumors
-
2025-520623-24-00
7
2025-11-19
MTAP-deleted Solid Tumors
-
2025-520746-30-00
5
2025-11-18
Mild to moderate Alzheimer’s Disease
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-511236-27-00
7
2025-11-12
High grade serous or endometroid ovarian cancer
-
2023-508612-29-00
5
2025-11-07
Advanced Melanoma
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2025-521522-15-00
4
2025-11-05
Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy
-
2025-520613-31-00
5
2025-10-31
Agitation Associated with Alzheimer’s Disease
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-503850-11-00
10
2025-10-28
Oligospermia and/or asthenozoospermia
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2025-521872-69-00
3
2025-10-28
Advanced/Metastatic Pancreatic Adenocarcinoma
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
-
2024-511459-16-00
9
2025-10-14
Histologically confirmed pancreatic adenocarcinoma with liver metastas
-
2024-512421-92-00
7
2025-10-14
Unresectable, Locally Advanced or Metastatic Cancer
-
2024-514974-39-00
5
2025-10-10
Developmental and Epileptic Encephalopathies (DEEs)
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-520156-22-00
4
2025-10-08
Metastatic hormone-sensitive prostate cancer
-
2024-520189-67-00
5
2025-10-08
OVARIAN CANCER
-
2025-521147-21-00
4
2025-10-08
Lung Cancer